809 related articles for article (PubMed ID: 30449001)
1. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
3. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
[TBL] [Abstract][Full Text] [Related]
4. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort.
Bonde AN; Martinussen T; Lee CJ; Lip GYH; Staerk L; Bang CN; Bhattacharya J; Gislason G; Torp-Pedersen C; Olesen JB; Hlatky MA
Circ Cardiovasc Qual Outcomes; 2020 Apr; 13(4):e006058. PubMed ID: 32283966
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
10. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
11. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
[TBL] [Abstract][Full Text] [Related]
12. Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series.
DeCamillo D; Ellsworth S; Kaatz S; Barnes GD
J Thromb Thrombolysis; 2020 Nov; 50(4):844-848. PubMed ID: 32219722
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Schafer JH; Casey AL; Dupre KA; Staubes BA
Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
[TBL] [Abstract][Full Text] [Related]
14. To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban.
Ciccone MM; Zito A; Devito F; Maiello M; Palmiero P
Curr Drug Targets; 2018; 19(6):581-584. PubMed ID: 26424386
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Davis DO; Davis KA
J Pharm Pract; 2018 Oct; 31(5):441-444. PubMed ID: 28803521
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
17. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
[TBL] [Abstract][Full Text] [Related]
18. Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study.
Weronska A; Papuga-Szela E; Broniatowska E; Undas A
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e743-e748. PubMed ID: 34321399
[TBL] [Abstract][Full Text] [Related]
19. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
20. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
